Durect Corp
DRRXDelisted Sep 11, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001082038
Durect Corp was delisted on Sep 11, 2025; its insiders filed their last Form 4 on Sep 16, 2025; 40 institutions reported holding it in 13F filings for Q2 2025, worth $4.44M in total; no superinvestor held it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 12:21 PM ET
Revenue flow, FY2024
Where the revenue went in FY2024, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2024: $8.32M (409.8% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 26, 2025 | Mar 27, 2024 | Feb 3, 2023 | Mar 7, 2022 | Feb 4, 2021 |
| Revenue | $2.03M | $8.55M | $19.3M | $14.0M | $30.1M |
| Cost of revenue | $78.0K | $1.72M | $1.59M | $1.96M | $1.41M |
| Research and development | $10.4M | $29.4M | $36.9M | $31.8M | $27.7M |
| Selling, general and administrative | $10.5M | $14.4M | $15.9M | $14.4M | $13.6M |
| Operating income | -$18.9M | -$36.9M | -$35.1M | -$34.3M | -$12.6M |
| Interest expense | – | – | $2.40M | $2.15M | $2.24M |
| Income tax | $0 | $0 | – | – | – |
| Net income | -$8.32M | -$27.6M | -$35.3M | -$36.3M | -$582.0K |
| EPS, basic | $-0.27 | $-1.05 | $-1.55 | $-0.16 | $0.00 |
| EPS, diluted | $-0.27 | $-1.20 | $-1.55 | $-0.16 | $0.00 |
| Weighted shares, basic | 30.9M | 26.3M | 22.8M | 225.0M | 199.5M |
| Weighted shares, diluted | 30.9M | 26.5M | 22.8M | – | – |
| Margins and growth | |||||
| Operating margin | -931.2% | -431.5% | -181.9% | -245.2% | -41.9% |
| Net margin | -409.8% | -323.2% | -183.2% | -259.5% | -1.9% |
| Revenue growth, year over year | −76.2% | −55.7% | +38.0% | −53.6% | +1.9% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 26, 2025 | Mar 27, 2024 | Feb 3, 2023 | Mar 7, 2022 | Feb 4, 2021 |
| Cash and equivalents | $11.0M | $28.4M | $43.5M | $49.8M | $21.3M |
| Accounts receivable | $453.0K | $1.26M | $3.42M | $6.48M | $940.0K |
| Inventory | $106.0K | $2.22M | $2.11M | $1.87M | $1.86M |
| Total current assets | $13.2M | $34.7M | $51.4M | $81.7M | $63.1M |
| Property, plant and equipment | $41.0K | $91.0K | $188.0K | $227.0K | $251.0K |
| Goodwill | $2.73M | $6.17M | $6.17M | $6.17M | $6.17M |
| Total assets | $18.3M | $45.2M | $60.1M | $92.0M | $75.6M |
| Accounts payable | $309.0K | $1.78M | $3.11M | $1.31M | $1.68M |
| Short-term debt | $0 | $16.7M | $21.2M | – | $884.0K |
| Total current liabilities | $7.71M | $27.0M | $34.0M | $10.1M | $10.7M |
| Long-term debt | – | $16.7M | $21.2M | $20.6M | $19.9M |
| Shareholders' equity | $9.13M | $14.8M | $25.0M | $57.8M | $40.1M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 26, 2025 | Mar 27, 2024 | Feb 3, 2023 | Mar 7, 2022 | Feb 4, 2021 |
| Operating cash flow | -$19.1M | -$34.4M | -$26.3M | -$37.3M | -$38.7M |
| Capital expenditures | $0 | $52.0K | $111.0K | $194.0K | $208.0K |
| Free cash flow | -$19.1M | -$34.5M | -$26.4M | -$37.5M | -$38.9M |
| Depreciation and amortization | $84.0K | $31.0K | $119.0K | $288.0K | $297.0K |
| Stock-based compensation | $2.00M | $2.54M | $2.46M | $2.69M | $2.17M |
| Investing cash flow | $18.0M | -$1.17M | $19.8M | $15.3M | $9.43M |
| Financing cash flow | -$16.3M | $20.5M | $83.0K | $50.5M | $15.7M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 98.2% | 29.7% | 12.7% | 19.2% | 7.2% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits. Stock splits since Dec 31, 2019, from 13F share counts: 1-for-10 in Q4 2022.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.